Sunny Pharmtech continues to strengthen its global footprint by securing additional drug approvals and expanding its international market presence.
Sunny Pharmtech reported NT$418 million in revenue last year, marking the second-highest performance in its history, driven by robust growth in pharmaceutical sales and profit-sharing ventures. Sunny Pharmtech continues to strengthen its global footprint by securing additional drug approvals and expanding its international market presence.